89bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company focused on innovative therapies for liver and cardio-metabolic diseases, will participate in several investor conferences in May 2022. Key events include:

• BofA Securities Healthcare Conference on May 10, 2022, at 4:20 p.m. EST.
• RBC Capital Markets Global Healthcare Conference on May 18, 2022, at 10:30 a.m. EST.
• H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 a.m. EST.

Webcasts of these presentations will be available on 89bio’s investor website.

SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the following upcoming investor conferences in May:

• BofA Securities 2022 Healthcare Conference
  
  Format: Presentation and one-on-one investor meetings
  Date: Tuesday, May 10, 2022
  Presentation Time: 4:20 p.m. EST

• 2022 RBC Capital Markets Global Healthcare Conference
  
  Format: Fireside chat and one-on-one investor meetings
  Date: Wednesday, May 18, 2022
  Presentation Time: 10:30 a.m. EST

• H.C. Wainwright Global Investment Conference
  
  Format: Presentation and one-on-one investor meetings
  Date: Tuesday, May 24, 2022
  Presentation Time: starting at 7:00 a.m. EST

The webcast of these presentations will be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

FAQ

What are the upcoming investor conferences for 89bio (ETNB) in May 2022?

89bio will participate in the following investor conferences in May 2022: BofA Securities Healthcare Conference on May 10 at 4:20 p.m. EST, RBC Capital Markets Global Healthcare Conference on May 18 at 10:30 a.m. EST, and H.C. Wainwright Global Investment Conference on May 24 starting at 7:00 a.m. EST.

What is the focus of 89bio (ETNB)?

89bio focuses on developing innovative therapies for liver and cardio-metabolic diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

Where can I access the webcasts of 89bio's (ETNB) presentations?

The webcasts of 89bio's presentations will be accessible in the investor section of 89bio’s website.

What is pegozafermin, the lead candidate of 89bio (ETNB)?

Pegozafermin is a specifically engineered FGF21 analog developed by 89bio, designed to treat non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG) with an extended half-life.

When will 89bio (ETNB) present at the BofA Securities Healthcare Conference?

89bio will present at the BofA Securities Healthcare Conference on May 10, 2022, at 4:20 p.m. EST.